Bio Financial Statements From 2010 to 2026
| BPTH Stock | USD 0.06 0.01 17.14% |
Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Path's main balance sheet or income statement drivers, such as , as well as many indicators such as . Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
Bio |
Bio Path Holdings OTC Stock Shares Outstanding Analysis
Bio Path's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Bio Path Shares Outstanding | 5.77 M |
Most of Bio Path's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Path Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Bio Path Holdings has 5.77 M of shares currently outstending. This is 96.81% lower than that of the Biotechnology sector and 94.6% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 98.99% higher than that of the company.
Bio Path Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bio Path's current stock value. Our valuation model uses many indicators to compare Bio Path value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Path competition to find correlations between indicators driving Bio Path's intrinsic value. More Info.Bio Path Holdings is number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bio Path by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bio Path's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Bio Path Financial Statements
Investors use fundamental indicators, such as Bio Path's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bio Path's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Bio OTC Stock
Bio Path financial ratios help investors to determine whether Bio OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Path security.